ArticleOncotarget2020
A novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties
Article in Oncotarget, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 21 citations in OpenAlex.
- Single-Chain Variable Fragment Fusion Proteins for Targeted Delivery and Therapy.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Imaging-guided optimization of biodistribution and antitumor efficacy of L19-based immunocytokines.Translational oncology · 2026Article
- Tumor-targeted IL2 promotes specific CD8Journal of experimental & clinical cancer research : CR · 2026Article
- Miniaturized IL-2/anti-IL-2 immunocytokines selectively activate and support theFrontiers in immunology · 2026Article
- Exploring the mechanism of fibronectin extra domain B in the tumor microenvironment and implications for targeted immunotherapy and diagnostics (Review).Molecular medicine reports · 2025Review
- Combinatorial treatment with upadacitinib abrogates systemic toxicity of a tumor-targeted IL-2 fusion protein.Journal for immunotherapy of cancer · 2025Article
- Selective activation of interleukin-2/interleukin-15 receptor signaling in tumor microenvironment using paired bispecific antibodies.Journal for immunotherapy of cancer · 2025Article
- Antibody-based delivery of interleukin-2 modulates the immunosuppressive tumor microenvironment and achieves cure in pancreatic ductal adenocarcinoma syngeneic mice.Journal of experimental & clinical cancer research : CR · 2025Article
- Expression patterns of fibroblast activation protein and extra-domain B fibronectin in canine malignant tumors.Frontiers in veterinary science · 2025Article
- Tumor-Homing Antibody-Cytokine Fusions for Cancer Therapy.OncoTargets and therapy · 2024Review
- Imaging the Alternatively Spliced D Domain of Tenascin C in a Preclinical Model of Inflammatory Bowel Disease.Molecular imaging and biology · 2023Article
- Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection.Cell reports · 2022Article
- Effect of non-repetitive linker on in vitro and in vivo properties of an anti-VEGF scFv.Scientific reports · 2022Article
- Design and Characterization of Novel Antibody-Cytokine Fusion Proteins Based on Interleukin-21.Antibodies (Basel, Switzerland) · 2022Article
- Advancements of Common Gamma-Chain Family Cytokines in Cancer Immunotherapy.Immune network · 2022Review
- Engineered antibody fusion proteins for targeted disease therapy.Trends in pharmacological sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The targeted delivery of interleukin-2 to the tumor is gaining attention as an avenue to potentiate the action of T and NK cells at the site of disease. We have previously described the fusion of the L19 antibody, specific to the EDB domain of fibronectin, with human interleukin-2, using a non-covalent homodimeric diabody format. Here, we describe four novel formats for the L19-IL2 fusion, featuring different arrangements of antibody and IL2. A comparative quantitative biodistribution analysis in tumor-bearing mice using radioiodinated proteins revealed that the novel format (L19L19-IL2, with the antibody in single-chain diabody format) exhibited the best biodistribution results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.